L’alternance C/Ø des verbes français : une analyse par contraintes et stratégies de réparation

L’alternance C(onsonne)/Ø en français, notamment dans la flexion verbale, est souvent causée par des violations de contraintes phonologiques. Les consonnes latentes sont analysées ici comme des consonnes flottantes - des consonnes malformées en forme sous-jacente parce sans unité de temps - qui violent le « principe de légitimation » selon lequel toute unité phonologique doit être incorporée dans une structure complète. Selon le contexte phonologique/ morphologique, une violation peut être « réparée » par l’élision de la consonne flottante ou l’insertion d’une unité de temps, d’où résulte partiellement l’alternance C/Ø. Contrairement aux traditionnels groupes verbaux, la distinction entre « radical à consonne flottante » et « radical à consonne permanente » permet de prédire la sélection de suffixes infinitifs.The French C(onsonant)/Ø alternation, notably in verbal inflection, is often triggered by phonological constraint violations. We analyze the consonants involved in this alternation as floating consonants, i.e. consonants without a timing unit. This violates the "Prosodic Licensing Principle" which states, roughly, that all phonological units must be incorporated in a complete structure. Depending on the phonological/ morphological context, a violation can be "repaired" either by deleting the floating consonant or by licensing it (e.g. by linking it to a timing unit). This accounts for the C/Ø alternation. Distinguishing between "floating consonant" and "fixed consonant" stems allows us to partly predict the infinitive suffix selection

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved

Eighteenth-century genomes show that mixed infections were common at time of peak tuberculosis in Europe

Tuberculosis (TB) was once a major killer in Europe, but it is unclear how the strains and patterns of infection at 'peak TB' relate to what we see today. Here we describe 14 genome sequences of M. tuberculosis, representing 12 distinct genotypes, obtained from human remains from eighteenth-century Hungary using metagenomics. All our historic genotypes belong to M. tuberculosis Lineage 4. Bayesian phylogenetic dating, based on samples with well-documented dates, places the most recent common ancestor of this lineage in the late Roman period. We find that most bodies yielded more than one M. tuberculosis genotype and we document an intimate epidemiological link between infections in two long-dead individuals. Our results suggest that metagenomic approaches usefully inform detection and characterization of historical and contemporary infections

The genetic basis and evolution of red blood cell sickling in deer

Crescent-shaped red blood cells, the hallmark of sickle-cell disease, present a striking departure from the biconcave disc shape normally found in mammals. Characterized by increased mechanical fragility, sickled cells promote haemolytic anaemia and vaso-occlusions and contribute directly to disease in humans. Remarkably, a similar sickle-shaped morphology has been observed in erythrocytes from several deer species, without obvious pathological consequences. The genetic basis of erythrocyte sickling in deer, however, remains unknown. Here, we determine the sequences of human β-globin orthologues in 15 deer species and use protein structural modelling to identify a sickling mechanism distinct from the human disease, coordinated by a derived valine (E22V) that is unique to sickling deer. Evidence for long-term maintenance of a trans-species sickling/non-sickling polymorphism suggests that sickling in deer is adaptive. Our results have implications for understanding the ecological regimes and molecular architectures that have promoted convergent evolution of sickling erythrocytes across vertebrates

Characterizing Uncertainty in the Visual Text Analysis Pipeline

International audienceCurrent visual text analysis approaches rely on sophisticated processing pipelines. Each step of such a pipeline potentially amplifies any uncertainties from the previous step. To ensure the comprehensibility and interoperability of the results, it is of paramount importance to clearly communicate the uncertainty not only of the output but also within the pipeline. In this paper, we characterize the sources of uncertainty along the visual text analysis pipeline. Within its three phases of labeling, modeling, and analysis, we identify six sources, discuss the type of uncertainty they create, and how theypropagate. The goal of this paper is to bring the attention of the visualization community to additional types and sources of uncertainty in visual text analysis and to call for careful consideration, highlighting opportunities for future research